Company news

Oruka Therapeutics, Inc. news in 2025

Oruka Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Oruka Therapeutics Announces New Board Member and Board Transition

December 10, 2025

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 11, 2025

Oruka Therapeutics to Present at Multiple November Investor Conferences

October 28, 2025

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

September 16, 2025

Oruka Therapeutics Announces $180 Million Private Placement

September 16, 2025

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 10, 2025

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

July 20, 2025

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

June 30, 2025

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 19, 2025

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

April 28, 2025

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

March 6, 2025

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 5, 2025

Oruka Therapeutics to Present at Multiple March Investor Conferences

February 18, 2025

Decks in 2025